Innovative Collaboration Aims to Enhance Maternal Health with ARPA-H Awarded Diagnostic Test

Sera Prognostics Partners for Maternal Health Initiative

Sera Prognostics Inc., recognized as The Pregnancy Company®, has embarked on an innovative journey aimed at enhancing maternal and neonatal health through cutting-edge technology. Recently awarded by the Advanced Research Projects Agency for Health (ARPA-H), Sera will collaborate with researchers from the University of California San Diego and Allegro MicroSystems on a significant research initiative worth $10.4 million.

This initiative, part of ARPA-H's Making Obstetrics Care Smart (MOCS) program, is designed to develop a revolutionary point-of-care diagnostic test that addresses the pressing issue of fetal hypoxia during childbirth. By utilizing a small maternal blood sample, the team aims to create a method that accurately assesses risks associated with low fetal oxygen levels, an essential aspect influencing outcomes during labor.

Addressing Challenges in Labor and Delivery

Fetal hypoxia is a serious condition that can severely affect newborns. The objective of the diagnostic test is to equip healthcare professionals with timely and objective data regarding the risk of this condition. Such insights can enable more informed intervention decisions, ultimately improving both maternal and neonatal outcomes while potentially reducing unnecessary medical procedures.

Zhenya Lindgardt, President and CEO of Sera Prognostics, expressed pride in this collaboration, stating, "We are proud to collaborate with UC San Diego and our partners on this important initiative supported by ARPA-H. This work signifies a shift in maternal healthcare from merely responding to complications to proactively identifying risks and facilitating early decision-making."

Sera Prognostics is dedicated to contributing its expertise in protein biomarker discovery and validation to help identify key biomarkers associated with placental functions, fetal stress, and risk of hypoxia. By integrating these biomarkers into a point-of-care testing platform, Sera envisions accelerating critical decisions that impact the safety of labor and delivery.

The Importance of Early Intervention

The broader implications of the MOCS initiative reflect a growing commitment to tackling persistent challenges in maternal health through innovative diagnostic technologies. Historical data reveals alarming statistics: preterm birth, defined as delivery before 37 weeks of gestation, remains a leading contributor to infant morbidity and mortality in the United States.

Recent reports indicate that, for several years, the U.S. has received low grades for preterm birth rates, underscoring the ongoing need for advancements in prenatal care. Sera’s PreTRM® Test, which accurately predicts the risk of spontaneous preterm births, exemplifies the kind of breakthrough anticipated from this collaboration. It utilizes protein analysis to provide individualized risk reports, enabling early interventions for women at higher risk of complications.

By focusing on proactive strategies rather than reactive measures, Sera Prognostics aims to significantly reduce healthcare costs associated with managing the long-term effects of prematurity, estimated at around $25 billion annually in the U.S. alone.

Future of Maternal and Neonatal Health

This partnership marks a pivotal movement toward enhancing the landscape of maternal and neonatal healthcare. As research continues to unfold, Sera Prognostics is committed to its mission of delivering precise, data-driven insights that can transform obstetrical care. As the program evolves, stakeholders anticipate that the findings will lead to improved clinical outcomes and enriched families’ experiences during childbirth.

In conclusion, the collaborative efforts spearheaded by Sera Prognostics signify a hopeful future for pregnant women and their babies. With innovative testing and a collaborative spirit among leading researchers, advancements in maternal health can soon become standard practice, fostering a safer environment for all involved in the birthing process.